Ultragenyx’s $203 Million Voucher Sale Adds a Non-Dilutive Cash Catalyst
Ultragenyx’s planned $203 million FDA voucher sale gives $RARE a potential cash catalyst without issuing new shares.
AbbVie Stock Reaches Record High After FDA Approves Parkinson’s Drug Juvmo
AbbVie’s $283.44 record high and FDA approval of Juvmo strengthen the company’s pipeline narrative without offering a forecast for sales or earnings.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
J&J Weighs Orthopedics Spinoff as Investors Reassess Its Portfolio and Valuation
Johnson & Johnson is reportedly leaning toward spinning out its hips-and-knees business, putting portfolio strategy and …
Ultragenyx’s $203 Million Voucher Sale Sets a New Cash Benchmark for Biotech
Ultragenyx’s agreed $203 million voucher sale could strengthen its balance sheet and give biotech investors a benchmark …
Galderma’s $1.5 Billion ZO Skin Health Deal Signals More Consolidation in Dermatology
Galderma’s $1.5 billion cash purchase of ZO Skin Health highlights continued consolidation across dermatology, skincare …
Vaxcyte Raises $1.15 Billion to Advance VAX-31 as PCVX Shares Surge
Vaxcyte’s $1.15 billion public offering strengthens funding for VAX-31 while putting shareholder dilution in sharper foc…
UnitedHealth Raises 2026 Earnings Outlook as Medical-Cost Management Supports Q3 Beat
UnitedHealth raised its 2026 adjusted earnings outlook to at least $20.50 per share after a Q3 beat, offering a key sign…
Bristol Myers Squibb Gains on Dual Phase 3 Wins and CAMZYOS Label Expansion
Bristol Myers Squibb shares gained on dual Phase 3 wins, CAMZYOS expansion and fresh analyst commentary on its IPF pipel…
Bristol Myers Squibb Stock Jumps 6.5% on Dual Phase 3 Wins and Expanded CAMZYOS Approval
Bristol Myers Squibb shares jumped 6.5% after two positive Phase 3 updates and expanded FDA approval for CAMZYOS strengt…
Syndax Stock Drops 12.2% After Axatilimab Trial Miss Raises Biotech Risk Concerns
Syndax shares fell 12.2% to $14.54 in pre-open trading after its MAXPIRe Phase 2 axatilimab trial did not meet expectati…
UnitedHealth Raises 2026 Profit Outlook as Q3 Beat Overcomes Medical-Cost Pressure
UnitedHealth topped Q3 estimates and raised its 2026 profit outlook, offering a closely watched signal for managed care …